AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1611652
Drug: Cefprozil (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil (administered once daily for ten days)
Trial: 1611652
Drug: Cefaclor (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (administered three times a day for ten days)
Trial: 6142351
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dose of metaraminol infusion
Trial: 6142351
Drug: Prophylactic colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic colchicine therapy
Trial: 25767259
Drug: GSK‐1614235 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK‐1614235 (20 mg) premeal dosing
Trial: 20690094
Drug: Early and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early and intensive statin therapy (60 mg immediately and 40 mg/day atorvastatin)
Trial: 20690094
Drug: Conventional statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional statin therapy (10 mg/day atorvastatin)
Trial: 19178799
Drug: Amoxicillin/clavulante for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulante for 3 weeks after FESS
Trial: 19178799
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic after FESS (Control group)
Trial: 16618013
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg DHEC (Almirid 40 mg test T)
Trial: 16618013
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 20 mg DHEC (Almirid 20 mg reference R)
Trial: 10576464
Drug: Paroxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10 to 40 mg daily)
Trial: 10576464
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 to 40 mg daily)
Trial: 6359887
Drug: Metoprolol (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (a beta 1‐adrenergic antagonist)
Trial: 6359887
Drug: High-dose terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose terbutaline
Trial: 6359887
Drug: Infusion dosages
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion dosages above 40 micrograms/min
Trial: 25006120
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine + volasertib (LDAC + volasertib)
Trial: 18072875
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg of calcium citrate daily (500 mg with meals)
Trial: 18072875
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of calcium citrate daily
Trial: 12970287
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/d (RLX60)
Trial: 12970287
Drug: Raloxifene 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 120 mg/d (RLX120)
Trial: 10792117
Drug: Rifaximin, 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin, 1200 mg/day (400 mg t.d.s.)
Trial: 10792117
Drug: Chlortetracycline, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlortetracycline, 1 g/day (333 mg t.d.s.)
Trial: 9240777
Drug: Intraoperative mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative mitomycin-C (0.04%) as a single dose
Trial: 1467256
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of social relations programme and cooperative learning
Trial: 30774069
Drug: DRIFT (drainage,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRIFT (drainage, irrigation and fibrinolytic therapy)
Trial: 30774069
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (cerebrospinal fluid tapping)
Trial: 19260949
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of simvastatin and bezafibrate
Trial: 16525137
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg once daily for 52 weeks
Trial: 10434907
Drug: Quantitative analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative analysis of enhancement patterns using T1 weighted spoiled gradient recalled echo (SPGR) images during bolus intravenous injection of 0.1 mmol kg‐1 of Gd‐chelate
Trial: 22186072
Drug: Pyrimethamine-sulphonamide treatment
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrimethamine-sulphonamide treatment for 3 months followed by Fansidar(®) for 9 months
Trial: 11049014
Drug: Prescribed drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed drugs
Trial: 11049014
Drug: Over-the-counter (OTC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-counter (OTC) drugs
Trial: 11049014
Drug: Central nervous
RxNorm normalized name: CENTRAL NERVOUS SYSTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central nervous system (CNS) drugs
Trial: 11049014
Drug: OTC drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTC drugs
Trial: 11049014
Drug: Potential drug
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential drug interactions
Trial: 9052345
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 or 20 mg) and Felodipine ER (2.5, 5, or 10 mg)
Trial: 9052345
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg) and Felodipine ER (10 mg)
Trial: 9052345
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg) and Felodipine ER (2.5 mg)
Trial: 3329515
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg benzhexol
Trial: 27070250
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration (WBV) treatment for 2 weeks, 14-minute sessions
Trial: 27070250
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration (WBV) treatment
Trial: 25023033
Drug: Sequential rescue
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential rescue therapies
Trial: 18710676
Drug: Self-reported daily
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported daily smoking
Trial: 18710676
Drug: Cotinine concentration
RxNorm normalized name: Chinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotinine concentration cutoff of 10 ng/mL
Trial: 18710676
Drug: Cotinine concentration
RxNorm normalized name: Chinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotinine concentration cutoff of 30 ng/mL
Trial: 12891299
Drug: simvastatin (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin (10‐20 mg/day), clopidogrel (75 mg/day), and trimetazidine (60 mg/day) for 6 months
Trial: 11146601
Drug: Anti epileptic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti epileptic medication
Trial: 8858649
Drug: Nebulizer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer treatment group
Trial: 8858649
Drug: MDI-spacer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI-spacer treatment group 1
Trial: 8858649
Drug: MDI-spacer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI-spacer treatment group 2
Trial: 3300424
Drug: Epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ketamine (4, 6, and 8 mg in saline; 6 mg in 10% glucose)
Trial: 8773867
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (3 mg)
Trial: 28962912
Drug: Lumbar transforaminal
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar transforaminal epidural steroid injections (TFESIs)
Trial: 23997095
Drug: PEMI after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEMI after sublingual administration of 5 mg of isosorbide dinitrate (ISDN)
Trial: 16583466
Drug: Single SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC doses of 0.5, 1.5, or 3.0 mg/kg
Trial: 16583466
Drug: SC doses
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC doses of 100 mg every 2 weeks (3 injections)
Trial: 16583466
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg IV infliximab every 2 weeks (2 infusions) followed by 100 mg SC every 2 weeks (3 injections)
Trial: 16583466
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg IM every 2 weeks (3 injections)
Trial: 16583466
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg SC every 4 weeks (3 injections)
Trial: 30945515
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (N=40)
Trial: 28760205
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation therapy with edoxaban
Trial: 28760205
Drug: Aspirin or
RxNorm normalized name: aspirin Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin or no antithrombotic therapy (control group)
Trial: 23381494
Drug: Intranasal mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mometasone furoate (MF)
Trial: 19351223
Drug: Aceclofenac-paracetamol combination
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac-paracetamol combination (100 mg aceclofenac + 500 mg paracetamol bid)
Trial: 19351223
Drug: Aceclofenac alone
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac alone (100 mg bid)
Trial: 19351223
Drug: Aceclofenac-paracetamol combination
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac-paracetamol combination
Trial: 17032347
Drug: Product of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product of insulin sensitivity and insulin secretion (B-beta)
Trial: 11444253
Drug: docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 100 mg/m2
Trial: 11444253
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m2
Trial: 11444253
Drug: vinorelbine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine 30 mg/m2 or ifosfamide 2 g/m2
Trial: 8053664
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human nerve growth factor (rhNGF) intravenous or subcutaneous doses ranging from 0.03 to 1 micrograms/kg
Trial: 8053664
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human nerve growth factor (rhNGF) at doses above 0.1 microgram/kg
Trial: 8053664
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human nerve growth factor (rhNGF) subcutaneous doses
Trial: 8053664
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human nerve growth factor (rhNGF) intravenous doses
Trial: 2970218
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate plus mitomycin-C (MMC)
Trial: 2970218
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate plus vindesine
Trial: 31674161
Drug: Neurofeedback augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofeedback augmentation group (n = 12)
Trial: 31674161
Drug: Medication-only (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-only (treatment as usual [TAU] group, n = 12)
Trial: 21218023
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (identical treatment program without insight enhancement)
Trial: 19110596
Drug: Granulocytic CSF
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granulocytic CSF (neupogen) added to chemotherapy
Trial: 19110596
Drug: Chemotherapy (adriablastine+taxotere)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (adriablastine+taxotere) without neupogen
Trial: 10739360
Drug: Granisetron (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (2 mg/m2) plus dexamethasone (8 mg/m2)
Trial: 10739360
Drug: Ondansetron (5.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (5.3 mg/m2) plus dexamethasone (8 mg/m2)
Trial: 10739360
Drug: Tropisetron (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (3.3 mg/m2) plus dexamethasone (8 mg/m2)
Trial: 10739360
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with IFO
Trial: 10739360
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with CDP/ADM
Trial: 8959118
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 1 mg day‐1
Trial: 8959118
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 2 mg day‐1
Trial: 1530423
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg isosorbide dinitrate once daily
Trial: 1530423
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide dinitrate three times daily
Trial: 6199177
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of mexiletine (200 mg three times daily) and propranolol (20 mg three times daily)
Trial: 25378931
Drug: High-H2 water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-H2 water containing 7 ppm H2 (3.5 mg H2 in 500 mL water)
Trial: 21819594
Drug: McKenzie treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McKenzie treatment program
Trial: 21819594
Drug: Back School
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back School treatment program
Trial: 11593067
Drug: Diuretics, digoxin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics, digoxin, angiotensin‐converting enzyme inhibitors, beta‐blockers; specific dosages and durations not available.
Trial: 8988914
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A dosing
Trial: 30709402
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention designed to reduce exposure to second-hand smoke; details on dosage and duration not specified.
Trial: 26405990
Drug: Conventional clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional clinical therapy
Trial: 23280141
Drug: Acetazolamide (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (125 mg Bid, n=11)
Trial: 15283899
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of finasteride daily for 7 years
Trial: 9470059
Drug: Captopril (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75 mg/day) plus losartan (25 mg/day)
Trial: 9470059
Drug: Captopril (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75 mg/day) plus placebo
Trial: 2451383
Drug: PUVA treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA treatment, 10 systemic treatments
Trial: 2451383
Drug: Mechlorethamine (HN2)
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechlorethamine (HN2) treatment, 3 weeks duration
Trial: 29742924
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Policosanol (POL) and Pentoxifylline (PTX)
Trial: 28904061
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) supplementation (4 decaffeinated GTE capsules containing 1,315 mg total catechins, including 843 mg EGCG for 12 months)
Trial: 21159789
Drug: 3.4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g/d EPA+DHA
Trial: 21159789
Drug: 0.85 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.85 g/d EPA+DHA
Trial: 9421348
Drug: Milnacipran (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (200 mg daily for weeks 2-10, flexible dosing 100-200 mg daily for weeks 11-26)
Trial: 9421348
Drug: Clomipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (150 mg daily for weeks 2-10, flexible dosing 75-150 mg daily for weeks 11-26)
Trial: 8098588
Drug: Vecuronium (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.12 mg.kg‐1; ED95 x 2)
Trial: 8098588
Drug: Atracurium (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.4 mg.kg‐1; ED95 x 2)
Trial: 3534583
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + TAM (10 mg three times daily for 1 yr)
Trial: 19929191
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) 30,000 U intravenous every 48 hours for 3 doses
Trial: 1632006
Drug: District psychiatric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: District psychiatric treatment after discharge
Trial: 6716990
Drug: NU-CHIPS administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NU-CHIPS administered in noise at S/N = -4
Trial: 6716990
Drug: NU-CHIPS administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NU-CHIPS administered in noise at S/N = 0
Trial: 6716990
Drug: NU-CHIPS administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NU-CHIPS administered in noise at S/N = +2
Trial: 28930912
Drug: ivabradine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine (5 mg twice daily) for 96 hours
Trial: 6411497
Drug: Pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200 mg/day)
Trial: 7583868
Drug: Oxatomide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (60 mg daily for 7 days)
Trial: 2153735
Drug: Acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 400 mg five times daily for 5 days
Trial: 28609349
Drug: IDEAL IMPLANT
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDEAL IMPLANT Core Study
Trial: 28609349
Drug: Other breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other breast implant trials (MemoryShape, Allergan 410, Sientra Core Studies)
Trial: 16385106
Drug: New therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapies in clinical trials
Trial: 16385106
Drug: Mechanism-based approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanism-based approach to treatment
Trial: 16385106
Drug: Study designs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study designs and potential solutions
Trial: 12236487
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid at doses of 600, 1200, and 1800 mg/day
Trial: 12236487
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of ursodeoxycholic acid (not specified)
Trial: 8582916
Drug: Topical RGD
RxNorm normalized name: Delta24-RGD
DrugBank: Tasadenoturev (DB17178)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical RGD peptide matrix